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ABSTRACT 
BACKGROUND 
Adverse effects from second line drugs 
used in MDRTB treatment include 
neuropsychiatric effects which are 
usually very significant as they may cause 
anxiety and lead to default and poor 
adherence by patients if quick 
recognition and intervention is not 
available. This case series aims highlight 
the occurrence of cycloserine related 
psychosis among patient on treatment for 
MDR-TB in Nigeria, with the objective of 
promoting adequate evaluation and 
quick response and treatment to this 
importantADR. 
METHOD 
he case records of 3 patients from two 
MDR-TB in-patient treatment centers in 
Nigeria and a review of the existing 
literature was utilized. Results 
RESULTS 
An association was found with the use of 
Cycloserine and development of Psychosis 
during the management of these patients 
with MDR-TB. Early recognition and 
quick treatment is required to ensure 
treatment continuation and resolution of 
theADR. 
CONCLUSION 
Patients with MDR-TB on Cycloserine 
containing CAT IV regimen should be 
monitored closely for neuropsychiatric 
side effects for early diagnosis, prevention 
and treatment. 
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INTRODUCTION 
Multidrug-resistant tuberculosis (MDR-TB), 
defined as TB resistant to isoniazid (H) and 
rifampicin (R) is a major concern in global TB 
control, 1 as it is thought that more than half a 
million MDR-TB cases emerge per year. 2 MDR-
TB is also a serious public health problem in 
Nigeria as it is estimated that 2.9% of new TB 
cases have MDR-TB while 14% ofretreatment 
cases have MDR TB, with Nigeria listed as a 
high burden country (HBC) for TB, DR TB and 
TB-HIY.2 
The drug regimens used in the treatment of 
drug susceptible Tuberculosis (TB) are 
associated with multisystem mild, moderate 
and severe side effects which include drug 
induced hepatitis, optic neuritis and 
peripheral neuropathy among others 3 • It is 
also known that the adverse effect profile 
reported for the second line drugs used in 
MDR-TB treatment are more severe than that 
of the first line drugs.3-7 
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The multisystem spectrum of adverse drug 
reaction (ADR) from second line drugs used in 
MDRTB treatment include neuropsychiatric 
effects which are usually very significant as 
they may cause anxiety and lead to default and 
poor adherence by patients if quick recognition 
and intervention is not available 4-8• 
With the diagnosis of MDR-TB and 
subsequent WHO approval of CAT IV/2oo.line 
treatment regimen5 for MDR-TB in Nigeria, it 
is expected that patients on MDR-TB 
treatment will present with these side effects. 
It is therefore evident that the management of 
MDR-TB in Nigeria with a treatment duration 
of 20months9will be confronted with 
challenges related to the increased adverse 
effect profile of 2nd line drugs: 
Although drug induced encephalopathy is not 
exclusive to MDR-TB drugs; 2nd line TB drugs 
have been documented to cause 
encephalopathy and a spectrum of 
neuropsychiatry effects such as headaches, 
depression, seizures, sleep disorders, 
psychoses and other mental disturbances. 5'6'10 
Levofloxacin, terizidone and Cycloserine are 
the MDR-TB second line drugs that have been 
the most implicated in CNS toxicity. Off all 
these, cycloserine has however been 
associated with a higher frequency of 
psychiatric and CNS related ADRs such as 
psychotic sates with suicidal tendencies 
compared to other second line drugs.10'11' Many 
reports associating cycloserine with psychosis 
have therefore been published from various 
countries.12'13 
Cycloserine (4-amino-3-isoxazolidinone) is a 
tuberculostaticantibiotic effective against 
Mycobacterium tuberculosis. Cycloserine 
works as an antibiotic by inhibiting cell-wall 
biosynthesis in bacteria.14' 15 As a cyclic 
analogue of D-alanine, cycloserine acts 
against two crucial enzymes important in the 
cytosolic stages of peptidoglycan synthesis: 
alanine racemase (Alr) and D-alanine:D-
alanine ligase (Ddl).15 The first enzyme is a 
pyridoxal 5'-phosphate-dependent enzyme 
which converts the L-alanine to the D-alanine 
form. 15 The second enzyme is involved in 
joining two of these D-alanine residues 
together by catalyzing the formation of the 
ATP-dependent D-alanine-D-alanine 
dipeptide bond between the resulting D-
alanine molecules. 15 If both of these enzymes 
are inhibited, then D-alanine residues cannot 
form and previously formed D-alanine 
molecules cannot be joined together.15 This 
effectively leads to inhibition of peptidoglycan 
synthesis.15Cycloserine is a broad spectrum 
antibiotic and has been classified by WHO as a 
second-line group IV oral bacteriostatic drug 
used in a dose of 250-500 mg twice 
daily. 3Cycloserine does not share cross 
resistance with other anti-mycobacterial 
agents and hence its choice for drug-resistant 
Tb (DR-TB). The adverse effects of Cycloserine 
are mainly dose-related and idiosyncratic16• 
Some Psychiatric symptoms such as anxiety, 
depression, paranoia, hallucinations, 
euphoria, behavioral changes and suicidality 
have been reported in 9. 7-50% of individuals 
on Cycloserine17; with these side effects most 
likely to occur during the first 12 weeks of 
treatment.17 
Cycloserine has been implicated to cause 
elevation of GABA due to inhibition of GABA 
transferase in studies on mice18• GABA has 
been implicated in delirium19, with studies 
suggesting that GABA activity is increased in 
delirium due to hepatic encephalopathy and 
decreased in delirium caused by 
hypnotic/sedative withdrawal. 20 Glutamate is 
another neurotransmitter that has been 
researched in the pathogenesis of delirium. 21'22 
Cycloserine also has effects on glutamatergic 
transmission through its actions on 
AMPNKainase and NMDA receptors.23 It can 
therefore be hypothesized that Cycloserine 
can cause delirium due to its actions on the 
GABA and glutamate neurotransmitter 
system. However, other factors that may 
exacerbate or precipitate psychosis in patents 
are concurrent medications such as 
Fluoroquinolone and clinical states like 
diarrhea. 23 
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The neurotoxic actions of cycloserine have also 
been demonstrated from an RCT study24 which 
showed that the psychotic effects of D-
cycloserine which are mediated by the NMDA 
receptor pathway resulted in worsening of 
psychotic symptoms and general 
psychopathology in schizophrenic patients in 
which addition of 100 mg D-cycloserine, to 
typical anti psychotics. 
In view of the negative perception of 
psychiatric diseases in Nigeria25'26 which 
results in stigmatization25, resistance to 
medical treatment and the preference for 
spiritual healing.26 It Is important that 
healthcare providers have the knowledge and 
expenence to manage cycloserine related 
psychosis. 
It is expected that this reports will contribute 
to pharmacovigilance and provide the 
experience and knowledge on CNS toxicity of 




A 48 year old female with diabetes, diagnosed 
with MDR-TB, was admitted in the inpatient 
services of a MDR-Tb treatment center in 
ATBU Teaching Hospital, North Eastern 
Nigeria. She was categorized as a new case 
since there was no previous history of 
tuberculous treatment and contact was 
traceable to her daughter who was 
successfully treated for MDR-Tb. She was HIV 
negative and did not have any past history of a 
psychiatric illness or hypertension. Her 
baseline investigations on admission which 
included serum electrolytes, liver function 
test, renal function test, complete blood count, 
and audiometry were normal. Her glycemic 
control was poor with an RBS of27mmol/l. She 
was thus rehydrated and switched from her 
OHAs to insulin with resulting good glycemic 
control. The patient was commenced on 
Cycloserine 500mg OD in addition to other 
CAT IV MDR-Tb drugs which included 
Kanamycin, Prothionamide, Levofloxacin, 
Pyrazinamide and Pyridoxine based on the 
National guideline for DR-Tb treatment. 9 Four 
days after commencement of treatment the 
patient was noticed to be have become 
withdrawn, irrational and suspicious of the co-
patients, accusing them of stealing her things 
and trying to poison her. A diagnosis of 
probable cycloserine induced psychosis was 
made and cycloserine was discontinued for 72 
hours pending a Neuropsychiatric review. The 
patient's symptoms resolved with the 
withdrawal of cylcoserine, but recommenced 
with the reintroduction of the drug with the 
patient becoming more violent, irrational, 
disruptive, hallucinating, insomniac and 
withdrawn. She was then commenced on 
initial 100mg dose of IM chlorpromazine 
followed by tabs Haloperidol 5mg BD and 
Benzhexol 5mg BD with a reduction in the 
dose of cylcoserine to 250mg daily. The 
patient's mental state improved with 
resolution of hallucinations, confusion, and 
normalization of sleep within 3 days, the dose 
of cycloserine was then scaled up to 500mg 
after 2weeks without a reoccurrence of 
symptoms. 
Case2 
23 year old male student, without diabetes or 
hypertension who had been diagnosed with 
MDR-TB, was admitted at the in-patient 
services of an MDR-Tb treatment center in the 
University of Port Harcourt Teaching 
Hospital, South-South, Nigeria. He had 
received 2 previous treatments for 
tuberculosis prior to diagnosis with category 1 
and II regimens. He was HIV negative and did 
not have any past history of a psychiatric 
illness and his baseline investigations at 
admission including electrolytes, liver 
function test, renal function test, complete 
blood count, and audiometry were normal. He 
was commenced on Cycloserine 500mg OD in 
addition to other CAT IV MDR-Tb drugs which 
included Capreomycin, Prothionamide, 
Levofloxacin, Pyrazinamide and Pyridoxine 
based on the National guideline for DR-Tb 
treatment. 9 Eight weeks after commencement 
of treatment the patient was noticed to have 
poor sleep, hyperactivity, agitation, irrelevant 
speech and unusual claims. There were no 
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hallucination and suicidal ideation. He was 
reviewed by the neuropsychiatrist who made a 
diagnosis of depressive psychosis probably 
induced by cycloserine. He was placed on 
100mg dose of IM chlorpromazine BD stat, 
followed by tabs risperidone 5mg BD and 
Haloperidol5mg BD. In spite of treatment for 
1 week the patient still had irrelevant talk, 
hyperactivity and agitation. Cycloserine was 
the withdrawn for one week with a resolution 
of symptoms. Cycloserine was then 
reintroduced in a graded pattern beginning 
with 250mg daily for two weeks and then 
escalated to 500mg daily. The dose of 
pyridoxine was also increased to 200mg daily. 
The patient remained in stable state until 
discharge. 
CaseS 
A 52 year old male with diabetes diagnosed 
with MDR-TB, was admitted in the inpatient 
services of a MDR-Tb treatment center in 
University of Port Harcourt Teaching 
Hospital, South South Nigeria. He had 
received previous treatment for Tuberculosis 
prior to diagnosis. He was HIV negative and 
did not have any past history of a psychiatric 
illness or hypertension. His baseline 
investigations at admission to the hospital 
including electrolytes, renal function, liver 
function test, complete blood count were 
normal. His baseline audiometry indicated 
hearing impairment. His glycemic control was 
poor with an RBS of 14 mmol/1; he was then 
switched to insulin which improved the 
glycemic control. He was commenced on 
Cycloserine 500mg OD in addition to other 2nd 
line MDR-Tb drugs which included 
Capreomycin, Prothionamide, Levofloxacin, 
Pyrazinamide and Pyridoxine based on the 
National guideline for DR-Tb treatment.9 
Three weeks after commencement of 
treatment the patient was noticed to refuse 
medications, became withdrawn and talked 
irrationally. He was also talkative with 
paranoid delusions, auditory and visual 
hallucination with destructive and violent 
behaviour. He was reviewed by the 
neuropsychiatrist who made a diagnosis of 
schizophrenia from probable cycloserine 
induced psychosis. He was placed on 100mg 
dose of IM chlorpromazine BD stat, followed 
by tabs risperidone 5mg BD, Haloperidol 5mg 
BD. Cycloserine dose was reduced to 250mg 
daily for 1 week and increased back to 500mg 
daily as the patient became stable within 4 
days of antipsychotic use. He continued his 
treatment and remained stable till his 
discharge. 
DISCUSSION 
The treatment ofMDR-TB is associated with a 
significant adverse effect profile which may 
impair the completion of treatment and 
patient adherence.4-6 Though all adverse 
reactions are serious; CNS toxicity and 
neuropsychiatric effects tend to be a more 
significant risk to the treatment ofMDR-TB as 
it is associated with increased morbidity, 
mortality and poor prognosis.8'16'17 These risk 
of treatment interruption is more likely in 
Nigeria due to the negative perception of 
psychiatric diseases and the socio cultural 
attitudes that promote refusal of medical 
treatment. 25'26 It is therefore imperative that 
CNS ADRs like pyschosis be taken seriously, 
identified early and treated promptly in order 
to ensure adherence with treatment. 
Cycloserine induced mania and psychosis has 
been reported in previous literatures.10-13 The 
prevalence of cycloserine psychiatric ADRs 
from a meta analysis of 27 studies with 2164 
patient is estimated to be 5. 7%10, while a South 
African study27 estimated a prevalence of 8.3% 
for psychosis and confusion in patients on 
cycloserine. Cycloserineis associated with a 
higher frequency of psychiatric and CNS-
relatedADRs than other second-line drugs27• 
It is reported that the psychiatric ADRs of 
cycloserine usually occur on the average 
within 12 weeks of treatment. This is in line 
with the duration of onset the 3 cases reported 
which ranged from 4days to 8weeks. It is 
however difficult to explain the risk or 
predisposition for the varied duration of onset. 
The spectrum of symptoms have also been 
found to vary among patients as seen from the 
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3 reported cases; as not all patients develop 
suicidal ideations, hallucinations, delusion 
and negative symptoms of schizophrenia. This 
variation seen among the cases may be 
explained by factors such as the premorbid 
state of the patients, as patients with 
schizophrenic psychotic predisposition make 
develop worsening of negative symptoms as a 
result of cycloserine use .. The exacerbation of 
schizophrenic symptoms may also be 
explained by the antagonistic effects of D-
cycloserine at the glycine recognition site of 
the NMDA receptor due to competition with 
the endogenous agonist glycine as shown in a 
study by van Berckel et al24' This makes the 
evaluation of the patient's premorbid 
psychiatric history an important part of the 
pretreatment assessment. Other possible 
factors are the interaction and neurotoxic 
effect of with other drugs like levofloxacin 
which has been shown to produce significant 
anxiety and insomnia as it also has effects on 
the NMDAand GABAsystems. 28 Consequently 
patients with these effects may tend to 
manifest with anxiety and insomnia as seen in 
one of the cases. The effect of cycloserine are 
also dose related27, therefore patients who 
receive effective higher doses will be more 
likely to present earlier and with more severe 
symptoms. This may occur in patients with 
better drug absorption and impaired liver 
function. 
There is no documented age or gender 
predisposition to the development of 
cycloserine induced psychosis. It has however 
been documented that factors such as the HIV 
status may have a role Cycloserine ADRs was 
to be significantly more common in patients 
who were HIV positive than in patients who 
were HIV negative with regard to peripheral 
neuropathy, psychosis and confusion. 27 
Though 2 of the reported patients were 
diabetic there is no documentation of diabetes 
as risk factor for CNS toxicity and ADR from 
cycloserine in patients with MDR-TB. 
The cases presented in this series can be 
attributed to cycloserine based on the Naranjo 
ADR probability score of ~ 6 for all the cases 
which suggests a significant probable 
association29• The resolution and recurrence of 
symptoms after withdrawal, dose reduction 
and reintroduction respectively are strong 
pointers in this regard. In addition none of the 
patients has any evidence of metabolic 
encephalopathy from either renal or hepatic 
impairment as their baseline tests were all 
within normal limits. It is thus important to 
note that baseline and monitoring for liver and 
renal function should be done in patient with 
the psychotic symptoms. 30 
In spite of the significant manifestation of 
cycloserine psychosis in the 3 reported cases 
all the patients continued their treatment. 
This is in accordance with earlier reports that 
psychiatric morbidities are not a 
contraindication to the treatment of patients 
for MDR-TB.31 The cases presented in this 
report have shown the psychiatric 
complications can be managed and treated 
without the need for treatment 
discontinuation. 
This case series illustrates the need for close 
monitoring of psychiatric adverse events in 
patients receiving regimens for MDR-TB in 
Nigeria. It is recommended that patients on 2nd 
line regimen for MDR-TB should have a proper 
psychiatric evaluation pretreatment in 
addition to a thorough evaluation of other 
confounding factors that might lead to a 
similar clinical picture. As multi-drug 
resistance becomes more prevalent, there is a 
need for close liaison between chest physicians 
and psychiatrists to ensure prompt and 
appropriate response and treatment of these 
adverse events as psychosis is associated with 
increased morbidity and the risk of poor drug 
adherence. 32 
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